Literature DB >> 8593965

Endocrine effects of erythropoietin.

H E Carlson1, M L Graber, M C Gelato, J M Hershman.   

Abstract

Uremic men may manifest a variety of hormonal abnormalities, including decreased serum concentrations of testosterone and thyroid hormones and increased serum levels of growth hormone and prolactin. Some previous investigations have reported that erythropoietin therapy may reverse these hormonal changes. To investigate this possibility further, we measured serum prolactin, testosterone, LH, FSH, TSH, free thyroxine, triiodothyronine, growth hormone and IGF-I in 21 generally elderly male hemodialysis patients before and during erythropoietin therapy; many of the patients also received an anabolic steroid or metoclopramide treatment. Despite a significant erythropoietic response in a majority of the subjects, no significant changes were seen in any of the hormonal parameters other than a small decrease in serum growth hormone concentrations. Advanced age and chronic illness in our patients may have played a role in limiting the hormonal response reported by others.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8593965

Source DB:  PubMed          Journal:  Int J Artif Organs        ISSN: 0391-3988            Impact factor:   1.595


  2 in total

1.  Correction of hemodialysis anemia is associated with significant increase in serum concentration of IGF-I in patients treated with erythropoietin: a randomized controlled study.

Authors:  Hussein A Sheashaa; Abdalla Khalil; Mohammed M El Aarman; Fagr B El-Shahat; Amal Selim; Soma Sherif Abd El-Gawad
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.370

Review 2.  The Role of the Multiple Hormonal Dysregulation in the Onset of "Anemia of Aging": Focus on Testosterone, IGF-1, and Thyroid Hormones.

Authors:  Marcello Maggio; Francesca De Vita; Alberto Fisichella; Fulvio Lauretani; Andrea Ticinesi; Graziano Ceresini; Anne Cappola; Luigi Ferrucci; Gian Paolo Ceda
Journal:  Int J Endocrinol       Date:  2015-12-08       Impact factor: 3.257

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.